

MARKET UPDATE

Prima Biomed completes deal with Trillium Therapeutics

Melbourne, Australia. 5 December 2005. Prima Biomed Limited ("Prima") (ASX: PRR) today announced the settlement of the sale of assets of its subsidiary Arthron Pty Ltd to Toronto-based Trillium Therapeutics Inc (Trillium) and the receipt of the first payment of US\$500,000.

The following consideration was received as per the terms of the agreement entered in October 2005:

- an upfront cash payment of US\$500,000 and
- 1.2 million Trillium shares representing 7% of the Trillium shares currently on issue.

Further cash and Trillium shares will be received as Trillium achieves milestones specified in the agreement. Assuming all of these milestones are achieved, and based on Trillium's current issued share capital, the potential exists to build up to a 19% equity holding in Trillium within four years.

The milestones relate to agreements established with AstraZeneca and ZymoGenetics by Arthron, which have been acquired by Trillium as part of the sale. The respective milestones and payment entitlements are:

- an additional cash payment of US\$75,000 by Trillium in December due on election by ZymoGenetics to extend into its second and final year of its option period
- additional equity on the execution of licenses by Trillium with ZymoGenetics and AstraZeneca and progression to Phase I clinical trial of any product arising from the prospective licencees or Trillium's in house development program.

"We are delighted to have completed this transaction which our Board has valued at AU\$3.8 million based on the upfront cash and shares received. In assessing the value of the transaction, the Board took into consideration Trillium's capacity to progress the Arthron technology and its current corporate relationships," said Mr Eugene Kopp, Executive Chairman of Prima. "However, potential for longer term value is enhanced through the right to grow our equity position in line with the advancement of the technology and Trillium's own corporate growth based on its other key programs. Trillium's agreement with Genentech is one such relationship that we see as potentially adding value to our equity in Trillium."

Note: Trillium's CEO Dr. Niclas Stiernholm is currently in Australia and meeting with current and potential investors of Prima to demonstrate the investment value in Trillium and the longer term benefits to Prima. A copy of the presentation is attached.

About Trillium Therapeutics Inc

Trillium is a private research and development company specializing in therapies that restore balance to the immune system in conditions such as autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases.

Since the closing of its Series A financing round, Trillium has secured a licensing deal with Genentech. Trillium received an upfront payment, and recurrent revenue for research funding and milestone payments (terms of which have not been disclosed). Genentech will be solely responsible for clinical development, regulatory approvals, manufacturing and commercialisation.

Trillium has commercial agreements with academic institutions such as University Health Network, Toronto, and with major pharmaceutical and biotechnology companies including Genentech and Medarex Inc.

Trillium's key investors include VenGrowth Advanced Life Sciences Fund, the Canadian Medical Discovery Funds and the Business Development Bank of Canada. These groups hold the majority of Trillium's shares on issue.

Company Contacts:

Company Enquiries	Mr Eugene Kopp	03 9854 5700
Media Enquiries	Rebecca Wilson	0417 382 391

This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward - looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward - looking statements are expressly qualified in their entirety by this cautionary statement.

About Prima BioMed Ltd

Prima BioMed (ASX: PRR) is a biotechnology company based in Melbourne and is developing technologies in the fields of immunology and cancer immunotherapy originating from the Austin Research Institute in Melbourne, Australia.

For further information, visit www.primabiomed.com.au